dorsaVi’s Q3 FY25 report reveals growing adoption of its AI-powered video movement analysis in the US, a new elite athlete research partnership, and the launch of a pioneering 3D ACL injury prevention test.
- AI Video Movement Analysis Platform adopted by 80+ US clinics within four months
- New commercial research project with ESPN-affiliated surgeon on elite athlete lower limb injuries
- Launch of first-of-its-kind 3D motion analysis test targeting ACL injury reduction
- Progress on critical data security clearances with major US clinical franchise
- Q3 FY25 sales revenue of $289k and net operating cash outflow of $468k
Commercial Momentum in the US
dorsaVi (ASX:DVL) has reported encouraging traction for its AI Powered Video Movement Analysis Platform, with over 80 clinics in the United States adopting the technology within just four months of its December 2024 launch. This rapid uptake underscores the platform’s appeal, which offers clinicians a sensor-free, scalable solution that reduces setup time by 90%, enabling faster patient assessments and improved clinic revenue streams.
Clinicians like Josh Hayes, Director of Sports Medicine at Banner Physical Therapy, highlight the platform’s ability to deliver objective movement data in seconds, enhancing patient communication and clinical decision-making. This feedback suggests dorsaVi’s AI video technology is becoming integral to modern physical therapy workflows.
Strategic Partnerships and Research Initiatives
The company has also secured a new commercial research project with Dr. Chirag Patel, a prominent US surgeon and ESPN injury expert. This collaboration focuses on optimising lower limb movement analysis for elite athletes across major US sports leagues, including the NFL and NBA. The project leverages dorsaVi’s wearable sensors, AI video tracking, and Research+ software, aiming to identify injury risk factors and improve athlete safety and performance.
Additionally, dorsaVi is advancing critical data and technology security clearances with a major US clinical franchise, a milestone that could unlock access to thousands of physical therapy centres nationwide. The company is investing in meeting stringent data security requirements, building on its FDA clearance and ISO27001 certification.
Innovation in Injury Prevention
Highlighting its innovation pipeline, dorsaVi launched a first-in-class 3D motion analysis test designed to reduce anterior cruciate ligament (ACL) injuries, a costly and prevalent issue in sports medicine. This test provides real-time, laboratory-grade insights into knee rotation and torque, previously measurable only in specialised biomechanics labs.
The new 3D knee assessment targets a multi-billion-dollar market encompassing elite sports, rehabilitation, and workplace health. By enabling clinicians and coaches to proactively assess injury risk, dorsaVi aims to set a new standard in ACL injury prevention and rehabilitation.
Exploring Blockchain for Data Security
In parallel, dorsaVi is exploring blockchain integration to enhance the security, integrity, and privacy of its biomechanical and health data. This initiative complements its AI-driven video tracking tools and aligns with growing industry demands for tamper-proof, decentralised data management. The company’s partnership with the privacy-focused Secret Network reflects a forward-looking approach to secure health data sharing.
Financial Position and Outlook
Financially, dorsaVi recorded Q3 FY25 sales revenue of $289,000 and cash receipts of $214,000, with net operating cash outflows of $468,000. The company ended the quarter with a cash balance of $770,427 and is actively reviewing acquisition opportunities to complement its growth strategy. While cash burn remains a consideration, management expresses confidence in continuing operations and is prepared to raise capital if necessary.
Bottom Line?
dorsaVi’s expanding US footprint and innovative product launches position it well for growth, but sustained investment and regulatory progress will be key to unlocking its full potential.
Questions in the middle?
- When will dorsaVi complete the critical data security clearance with the major US clinical franchise?
- How quickly can the 3D ACL injury prevention test gain adoption among elite sports and rehabilitation providers?
- What are the commercial prospects and timelines for integrating blockchain technology into dorsaVi’s platforms?